摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-7-<5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-α-D-ribofuranosyl>-7H-pyrrolo<2,3-d>pyrimidine | 120401-30-1

中文名称
——
中文别名
——
英文名称
4-chloro-7-<5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-α-D-ribofuranosyl>-7H-pyrrolo<2,3-d>pyrimidine
英文别名
4-chloro-7-[5-O-[(1,1-dimethylethyl)dimethysilyl]-2,3-O-(1-methylethylidene)-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine;4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsilyl-α-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine;[(3aR,4S,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy-tert-butyl-dimethylsilane
4-chloro-7-<5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-α-D-ribofuranosyl>-7H-pyrrolo<2,3-d>pyrimidine化学式
CAS
120401-30-1
化学式
C20H30ClN3O4Si
mdl
——
分子量
440.014
InChiKey
PTFANUVYJLNMOM-ADAWSYLGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    523.9±50.0 °C(Predicted)
  • 密度:
    1.29±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.52
  • 重原子数:
    29.0
  • 可旋转键数:
    4.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.7
  • 拓扑面积:
    67.63
  • 氢给体数:
    0.0
  • 氢受体数:
    7.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-chloro-7-<5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-α-D-ribofuranosyl>-7H-pyrrolo<2,3-d>pyrimidine三氟乙酸 作用下, 以72%的产率得到4-chloro-7-(α-D-ribofuranosyl)-7H-pyrrolo<2,3-d>pyrimidine
    参考文献:
    名称:
    立体异构合成纯D-呋喃呋喃糖基氯化物制备吡咯并[2,3- d ]嘧啶α-和β-D-核糖核苷:固液相转移糖基化和15 N-NMR光谱
    摘要:
    固-液相转移的糖基化(KOH,三[2-(2-甲氧基乙氧基)ethye]胺(TDA =-1),MeCN中)吡咯并[2,3的d ]嘧啶类,例如图3a和3b中与等摩尔量5- O -[(1,1-二甲基乙基)二甲基甲硅烷基] -2,3 - O-(1-甲基亚乙基)-α-D-呋喃呋喃糖基氯(1)的制备[6]得到了保护的β-D-核苷4a和图4b分别是立体选择性地(方案)。β-D-异头物2 [6]得到相应的带有痕量β-D-化合物的α-D-核苷5a和5b。6-取代的7-脱氮嘌呤核苷6a,7a和8被转化为结核菌素(10)或其α-D-异头物(11)。异头核糖核苷自旋-晶格弛豫测量表明Ť 1个在α-d系列HC的值(8)的增加相比,HC(8)在β-d系列显著而相对的对为真Ť 1的HC(1')。分配了6个取代的7-脱氮嘌呤D-核呋喃糖苷的15 N-NMR数据,并将其与2'-脱氧化合物的15 N-NMR数据进行了比较。此
    DOI:
    10.1002/hlca.19880710623
  • 作为产物:
    参考文献:
    名称:
    立体异构合成纯D-呋喃呋喃糖基氯化物制备吡咯并[2,3- d ]嘧啶α-和β-D-核糖核苷:固液相转移糖基化和15 N-NMR光谱
    摘要:
    固-液相转移的糖基化(KOH,三[2-(2-甲氧基乙氧基)ethye]胺(TDA =-1),MeCN中)吡咯并[2,3的d ]嘧啶类,例如图3a和3b中与等摩尔量5- O -[(1,1-二甲基乙基)二甲基甲硅烷基] -2,3 - O-(1-甲基亚乙基)-α-D-呋喃呋喃糖基氯(1)的制备[6]得到了保护的β-D-核苷4a和图4b分别是立体选择性地(方案)。β-D-异头物2 [6]得到相应的带有痕量β-D-化合物的α-D-核苷5a和5b。6-取代的7-脱氮嘌呤核苷6a,7a和8被转化为结核菌素(10)或其α-D-异头物(11)。异头核糖核苷自旋-晶格弛豫测量表明Ť 1个在α-d系列HC的值(8)的增加相比,HC(8)在β-d系列显著而相对的对为真Ť 1的HC(1')。分配了6个取代的7-脱氮嘌呤D-核呋喃糖苷的15 N-NMR数据,并将其与2'-脱氧化合物的15 N-NMR数据进行了比较。此
    DOI:
    10.1002/hlca.19880710623
点击查看最新优质反应信息

文献信息

  • 6-(Het)aryl-7-Deazapurine Ribonucleosides as Novel Potent Cytostatic Agents
    作者:Petr Nauš、Radek Pohl、Ivan Votruba、Petr Džubák、Marián Hajdúch、Ria Ameral、Gabriel Birkuš、Ting Wang、Adrian S. Ray、Richard Mackman、Tomas Cihlar、Michal Hocek
    DOI:10.1021/jm901428k
    日期:2010.1.14
    A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or lietaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-clilot-o-(7-h ilogeiiztted-)7-deiz ipurine ribonucleosides with alkyl- or (het)arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-lialogen tted-)7-de iz tl)tii-iiie ri bon ucleos ides with (het)arylboronic acids. Significant cytostatic effect was detected With a Substantial proportion ofthe prepared compounds. The most potent were 7-H or 7-17 derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabinc. lntr icel]Lll ll'pliosphoi-yl itioil to niono- and triphosphates and the inhibition of total RNA synthesis was denionstrated in preliminary study of metabolism and tinechanistin of action Studies.
  • Structure−Activity Relationships of 7-Deaza-6-benzylthioinosine Analogues as Ligands of<i>Toxoplasma gondii</i>Adenosine Kinase
    作者:Young Ah Kim、Ashoke Sharon、Chung K. Chu、Reem H. Rais、Omar N. Al Safarjalani、Fardos N. M. Naguib、Mahmoud H. el Kouni
    DOI:10.1021/jm800201s
    日期:2008.7
    Several 7-deaza-6-benzylthioinosine analogues with varied substituents on aromatic ring were synthesized and evaluated against Toxoplasma gondii adenosine kinase (EC.2.7.1.20). Structure-activity relationships indicated that the nitrogen atom at the 7-position does not appear to be a critical structural requirement. Molecular modeling reveals that the 7-deazapurine motif provided flexibility to the 6-benzylthio group as a result of the absence of H-bonding between N7 and Thr140. This flexibility allowed better fitting of the 6-benzylthio group into the hydrophobic pocket of the enzyme at the 6-position. In general, single substitutions at the para or meta position enhanced binding. On the other hand., single substitutions at the ortho position led to the loss of binding affinity. The most potent compounds, 7-deaza-p-cyano-6-benzylthioinosine (IC(50) = 5.3 mu M) and 7-deaza-p-methoxy-6-benzylthioinosine (IC(50) = 4.6 mu M), were evaluated in cell culture to delineate their selective toxicity.
  • ROSEMEYER, HELMUT;SEELA, FRANK, HELV. CHIM. ACTA, 71,(1988) N 6, C. 1573-1585
    作者:ROSEMEYER, HELMUT、SEELA, FRANK
    DOI:——
    日期:——
查看更多

同类化合物

聚(7-去氮杂鸟苷酸) 羧鸟苷霉素 硫代桑吉瓦霉素 桑霉素 核苷Q 杀结核菌素5'-三磷酸酯 杀结核菌素-5'-二磷酸酯 杀结核菌素 木糖基杀结核菌素 乙酰腈,羰基[(2-噻嗯基亚甲基)肼基<联氨基>]-(9CI) [3,4-二乙酰氧基-5-(5-氧代-2,4,9-三氮杂双环[4.3.0]壬-3,7,10-三烯-9-基)四氢呋喃-2-基]甲基乙酸酯 N4-环丙基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-2,4-二胺 7-脱氮水粉蕈素 7-脱氮-2'-C-乙炔腺苷 7-溴-9-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-2,4,9-三氮杂双环[4.3.0]壬-3,7,10-三烯-5-酮 7-去氮杂肌苷 7-去氮-AMP 7-{5-O-[二甲基(2-甲基-2-丙基)硅烷基]-2,3-O-异亚丙基-beta-D-来苏呋喃糖基}-4-甲氧基-7H-吡咯并[2,3-d]嘧啶-2-胺 7-beta-D-阿拉伯呋喃糖基-7H-吡咯并[2,3-d]嘧啶-4-胺 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-7H-吡咯并[2,3-d]嘧啶-2-胺 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-7H-吡咯并[2,3-d]嘧啶 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-5-碘-7H-吡咯并[2,3-d]嘧啶 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-5-甲基-7H-吡咯并[2,3-d]嘧啶 7-(beta-D-来苏呋喃糖基)-4-甲氧基-7H-吡咯并[2,3-d]嘧啶-2-胺 7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-4-胺 6-氯-9-(beta-D-呋喃核糖基)-7-脱氮嘌呤 5-碘代杀结核菌素 5-碘-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-4-胺 5-甲基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-4-胺 5-溴杀结核菌素 5-氯杀结核菌素 5-(甲氧羰基)杀结核菌素 4-氯-7-{5-O-[二甲基(2-甲基-2-丙基)硅烷基]-2,3-O-异亚丙基-beta-D-来苏呋喃糖基}-7H-吡咯并[2,3-d]嘧啶-2-胺 4-氯-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-2-胺 4-氯-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氯-7-(2-C-乙炔基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氯-7-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氯-5-碘-7-(beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-2-胺 4-氯-5-碘-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氯-5-碘-7-(2-C-甲基-BETA-D-呋喃核糖基)-7H-吡咯并[2,3-D]嘧啶-2-胺 4-氯-5-甲基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氨基-7-beta-D-呋喃核糖基-7H-吡咯并[2,3-d]嘧啶-5-甲醇 4-氨基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-5-甲腈 4-氨基-6-氯-7-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]吡咯并[5,4-d]嘧啶-5-甲酰胺 4-氨基-5-氰基-7-(beta-d-呋喃核糖)吡咯并[2,3-d]嘧啶 4-(甲基硫烷基)-7-(5-O-磷羧基五呋喃糖基)-7H-吡咯并[2,3-d]嘧啶 3-氨基脱氮腺苷二氯铂(II) 2-氨基-7-[(2R,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-4-氧代-1H-吡咯并[4,5-e]嘧啶-5-甲脒 2-氨基-1,7-二氢-7-beta-D-呋喃核糖基-4H-吡咯并[2,3-d]嘧啶-4-酮 (S)-4-氨基-6-溴-7-((3R,4S,5R)-3,4-二羟基-5-羟基甲基-四氢-呋喃-2-基)-7,7alpha-二氢-4aH-吡咯并[2,3-d]嘧啶-5-甲腈